ATAC21|CAS 2101204-23-1|DC Chemicals

Cas No.:	2101204-23-1
Chemical Name:	ATAC21
SMILES:	O[C@H]1[C@@H](O[C@@]2([H])[C@@]1([H])OP(O)(OC[C@]3([H])[C@@]([C@H]([C@H](N4C5=C(C(N=C(N5)N)=O)N=C4)O3)O)([H])OP(O)(OC2)=O)=O)N6C7=NC=NC(NC(CCOCCOCCOCCOCCNC(CCN8C(C=CC8=O)=O)=O)=O)=C7N=C6
Formula:	C₃₈H₅₀N₁₂O₂₁P₂
M.Wt:	1072.82
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC74470	SuO-Val-Cit-PAB-MMAE	A drug-linker conjugate for antibody-drug conjugate by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the cleavable peptide SuO-Val-Cit-PAB..
DC72532	Fmoc-VAP-MMAE	Fmoc-VAP-MMAE is a drug-linker conjugates for ADC. Fmoc-VAP-MMAE consists of an ADC linker and a tubulin inhibitor MMAE, with a protective Fmoc group.
DC72119	Deruxtecan analog 2	Deruxtecan analog 2 (example 9 P3) is a Deruxtecan analog. Deruxtecan analog 2 is a drug-linker conjugate composed of Camptothecin and a linker. Camptothecin (CPT) is a Topo I inhibitor with antineoplastic activity against colorectal, breast, lung and ovarian cancers. Deruxtecan analog 2 can be used for the preparation anti-FGFR2 ADC.
DC71950	Ac-Lys-Val-Cit-PABC-MMAE	Ac-Lys-Val-Cit-PABC-MMAE is a drug-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor MMAE.
DC71666	MC-VA-PABC-MMAE	MC-VA-PABC-MMAE is a drug-linker conjugate for ADC. MC-VA-PABC-MMAE contains the ADCs linker (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE.
DC71665	Val-Cit-PAB-MMAF	Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF.
DC71664	Val-Cit-PAB-MMAF sodium	Val-Cit-PAB-MMAF sodium is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF sodium contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF.
DC71115	SN38 NHS ester	SN38 NHS ester is the NHS ester derivative of SN38. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis. SN38 NHS ester can be used for the synthesis of antibody-drug conjugates (ADCs).
DC50214	MC-Val-Cit-PAB-DX8951	MC-Val-Cit-PAB-DX8951 is a drug-linker conjugate for ADC. MC-Val-Cit-PAB-DX8951 is composed of a DNA topoisomerase I DX-8951 and a cathepsin cleavable ADC linker.
DC48385	MC-VC-PABC-amide-PEG1-CH2-CC-885	MC-VC-PABC-amide-PEG1-CH2-CC-885 is an Antibody-Drug Conjugates (ADC) based on protein degrading agent (protac molecular glue, etc.).